ORAMED PHARMACEUTICALS INC.
About ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.0M
- Net income
- $64.0M
- Total assets
- $230.9M
- Market cap
- $151.8M
- Gross margin
- 0.7%
- Operating margin
- -754.4%
- Net margin
- 3200.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.0M
- Cost of revenue
- $2.0M
- Gross profit
- $13.0K
- Operating expenses
- $15.1M
- Operating income
- -$15.1M
- Income tax
- $11.3M
- Net income
- $64.0M
- EPS (basic)
- $1.53
- EPS (diluted)
- $1.50
Balance sheet
- Total assets
- $230.9M
- Current assets
- $133.3M
- Total liabilities
- $31.1M
- Current liabilities
- $19.1M
- Shareholders’ equity
- $199.7M
Cash flow
- Operating cash flow
- -$9.1M
- Investing cash flow
- $5.4M
- Financing cash flow
- -$4.7M
- Net cash flow
- -$8.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $151.8M
- P/E ratio
- 2.4
- EPS (diluted)
- $1.5
- Shares outstanding
- 41.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 19, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $64.0M in FY2025.
- Revenue declined 26% from FY2021 to FY2025.
- Gross margin of 0.7%, net margin 3200.8%.
- Trading 23% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 2.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ORAMED PHARMACEUTICALS INC..
Write a review
News about ORAMED PHARMACEUTICALS INC.
News & sentiment via Polygon.io
